CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Sales-type Lease, Revenue
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Sales-type Lease, Revenue of $8.70 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SalesTypeLeaseRevenue · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for the quarter ending 2026-06-27 was $8.70M, a 28.10% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for the quarter ending 2026-03-28 was $12.20M, a 5.17% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for the quarter ending 2025-12-27 was $13.20M, a 10.20% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for the quarter ending 2025-09-27 was $12.10M, a 27.11% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for fiscal 2025 was $48.90M, a 29.13% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for fiscal 2024 was $69.00M, a 25.89% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for fiscal 2023 was $93.10M, a 54.91% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. sales-type lease, revenue for fiscal 2022 was $60.10M, a 231.71% increase from fiscal 2021.
| Period end | Sales-type Lease, Revenue 3 month | Sales-type Lease, Revenue 3 month as first filed | Sales-type Lease, Revenue 6 month | Sales-type Lease, Revenue 6 month as first filed | Sales-type Lease, Revenue 9 month | Sales-type Lease, Revenue 9 month as first filed | Sales-type Lease, Revenue 12 month | Sales-type Lease, Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $8.70M 10-Q · filed 2026-08-05 | $20.90M 10-Q · filed 2026-08-05 | $34.10M derived: sum of 3 quarters · filed 2026-08-05 | $46.20M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | $12.20M 10-Q · filed 2026-05-07 | $25.40M derived: sum of 2 quarters · filed 2026-05-07 | $37.50M derived: sum of 3 quarters · filed 2026-05-07 | $49.60M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-27 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $25.30M derived: sum of 2 quarters · filed 2026-02-18 | $37.40M derived: sum of 3 quarters · filed 2026-08-05 | $48.90M 10-K · filed 2026-02-18 | ||||
| 2025-09-27 | $12.10M 10-Q · filed 2025-11-05 | $24.20M derived: sum of 2 quarters · filed 2026-08-05 | $35.70M 10-Q · filed 2025-11-05 | $50.50M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $12.10M 10-Q · filed 2026-08-05 | $23.60M 10-Q · filed 2026-08-05 | $38.40M derived: sum of 3 quarters · filed 2026-08-05 | $55.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $11.60M 10-Q · filed 2026-05-07 | $26.30M derived: sum of 2 quarters · filed 2026-05-07 | $42.90M derived: sum of 3 quarters · filed 2026-05-07 | $59.60M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-28 | $14.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $31.30M derived: sum of 2 quarters · filed 2026-02-18 | $48.00M derived: sum of 3 quarters · filed 2026-02-18 | $69.00M 10-K · filed 2026-02-18 | ||||
| 2024-09-28 | $16.60M 10-Q · filed 2025-11-05 | $16.62M 10-Q · filed 2024-11-06 | $33.30M derived: sum of 2 quarters · filed 2025-11-05 | $54.30M 10-Q · filed 2025-11-05 | $54.31M 10-Q · filed 2024-11-06 | $77.17M derived: sum of 4 quarters · filed 2026-02-18 | ||
| 2024-06-29 | $16.70M 10-Q · filed 2025-08-06 | $16.72M 10-Q · filed 2024-08-07 | $37.70M 10-Q · filed 2025-08-06 | $37.69M 10-Q · filed 2024-08-07 | $60.56M derived: sum of 3 quarters · filed 2026-02-18 | $82.82M derived: sum of 4 quarters · filed 2026-02-18 | ||
| 2024-03-30 | $21.00M 10-Q · filed 2025-05-07 | $20.97M 10-Q · filed 2024-05-09 | $43.87M derived: sum of 2 quarters · filed 2026-02-18 | $66.12M derived: sum of 3 quarters · filed 2026-02-18 | $90.01M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2023-12-30 | $22.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $45.12M derived: sum of 2 quarters · filed 2026-02-18 | $69.01M derived: sum of 3 quarters · filed 2026-02-18 | $93.10M 10-K · filed 2026-02-18 | $93.10M 10-K · filed 2024-02-14 | |||
| 2023-09-30 | $22.25M 10-Q · filed 2024-11-06 | $46.15M derived: sum of 2 quarters · filed 2024-11-06 | $70.23M 10-Q · filed 2024-11-06 | $92.78M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-07-01 | $23.89M 10-Q · filed 2024-08-07 | $47.98M 10-Q · filed 2024-08-07 | $70.52M derived: sum of 3 quarters · filed 2025-02-19 | $86.31M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-04-01 | $24.09M 10-Q · filed 2024-05-09 | $46.63M derived: sum of 2 quarters · filed 2025-02-19 | $62.42M derived: sum of 3 quarters · filed 2025-02-19 | $76.33M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $22.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $38.33M derived: sum of 2 quarters · filed 2025-02-19 | $52.24M derived: sum of 3 quarters · filed 2025-02-19 | $60.10M 10-K · filed 2025-02-19 | $60.12M 10-K · filed 2023-02-22 | |||
| 2022-09-24 | $15.79M 10-Q · filed 2023-11-08 | $15.80M 10-Q · filed 2022-11-02 | $29.70M derived: sum of 2 quarters · filed 2023-11-08 | $37.56M 10-Q · filed 2023-11-08 | $37.60M 10-Q · filed 2022-11-02 | $44.08M derived: sum of 4 quarters · filed 2024-02-14 | ||
| 2022-06-25 | $13.91M 10-Q · filed 2023-08-09 | $13.90M 10-Q · filed 2022-08-03 | $21.77M 10-Q · filed 2023-08-09 | $21.80M 10-Q · filed 2022-08-03 | $28.29M derived: sum of 3 quarters · filed 2024-02-14 | $33.59M derived: sum of 4 quarters · filed 2024-02-14 | ||
| 2022-03-26 | $7.86M 10-Q · filed 2023-05-11 | $7.90M 10-Q · filed 2022-05-04 | $14.37M derived: sum of 2 quarters · filed 2024-02-14 | $19.67M derived: sum of 3 quarters · filed 2024-02-14 | $25.97M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2021-12-25 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $11.82M derived: sum of 2 quarters · filed 2024-02-14 | $18.12M derived: sum of 3 quarters · filed 2024-02-14 | $18.12M 10-K · filed 2024-02-14 | $18.10M 10-K · filed 2022-02-16 | |||
| 2021-09-25 | $5.30M 10-Q · filed 2022-11-02 | $11.60M derived: sum of 2 quarters · filed 2022-11-02 | $11.60M 10-Q · filed 2022-11-02 | |||||
| 2021-06-26 | $6.30M 10-Q · filed 2022-08-03 | $6.30M 10-Q · filed 2022-08-03 | ||||||
| 2020-12-26 | $0.00 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |